UBS Group lowered the Target Price of Hutchmed (China) (00013.HK) to 38.7 yuan with a rating of "Buy".

The UBS Group research report cites Hutchmed (China) management stating that the timeline for the sale of Shanghai Hutchmed is on schedule, with the Trade expected to be completed in the first quarter of this year. Management indicated that this divestment is expected to generate an investment return of 0.477 billion USD, and the cash obtained will help the company focus on the research and development of innovative therapies, especially in the antibody-targeted conjugate therapy (ATTC) platform. The firm anticipates that the company will achieve sustainable profits from 2025, with net profit expected to increase to 0.452 billion USD, although the net profit forecasts for 2026 and 2027 have been lowered by 55.6% and 39.5% respectively. The firm has set the company’s Target Price at

AASTOCKSJan 8 11:56

BOCOM INTL: Maintains Buy rating for Hutchmed (China) (00013) with the Target Price raised to 44 HKD.

BOCOM INTL believes that the conditions of this Trade involving Hutchmed (China) are reasonable and beneficial for the company's long-term development.

Zhitong FinanceJan 8 09:12 · Ratings

Hutchmed (China) sold Traditional Chinese Medicine Assets and gained $0.477 billion, with a commitment that the annual profit will grow by at least 5% over three years.

The management stated that the expected revenue from this sale is approximately $0.477 billion, which is pre-tax income, most of which will be recognized in 2025. This Trade has a three-year transition period, and subsequent income will be recognized gradually in 2026 and 2027.

lanjinger.comJan 7 20:54

BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Cuts Target Price to $26

Futu NewsJan 7 20:31 · Ratings

Hong Kong Stock Market Afternoon Review | All three major indices fell, with the Hang Seng Index down nearly 2%; Network Technology stocks declined, with Tencent down nearly 7% and Xiaomi down over 8%; some mineral stocks rose against the trend, with CGN

Network Technology stocks fell, with XIAOMI-W down 8.13% and TENCENT down 6.79%; Biotechnology stocks declined, with EVEREST MED-B down 6.35% and WUXI BIO down 4.22%; Shipping and Ports stocks weakened, with COSCO Shipping Holdings down 3.47% and CHINA MER PORT down 2.49%.

Futu NewsJan 7 12:23

Express News | Trump: Reports regarding the imposition of general tariffs on key imported Commodities are inaccurate.

BreakingsJan 6 22:17